Recursion Pharmaceuticals (RXRX) Stock Price
$5.66 7.4%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
3 -
Technical
5
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals. Scores are designed to reflect relative strength or weakness across these factors, helping users compare companies and track changes over time.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals' last reported revenue was $14.7M, marking a significant increase of 226.9% from the previous quarter and a slight year-over-year growth of 2.3%. However, the company's gross profit is in negative territory at -$7.1M, which has improved by 14.5% from the last quarter but deteriorated significantly year over year by -637.5%. The operating income also reveals a loss of -$191.4M, exhibiting a marginal quarterly decrease of -4.1% and a substantial annual decline of -90.3%. The EBITDA ratio stands at -12.98 reflecting poor profitability.
Stock Price
The stock is currently trading at $5.86 with an increase of 22.9% over the past month but has declined by -15.6% on a yearly basis indicating volatility in its performance.The RSI value is at 56.29 suggesting that it's neither oversold nor overbought while PE ratio being negative indicates no earnings for its shareholders.The stock's price movement appears to be slightly above its 200-day moving average ($5.8), implying a short-term bullish trend.
Alternative Data Signals
The website traffic shows an estimated volume of 68352 visitors per month which has marginally decreased by -0 .2%, possibly indicating waning interest or engagement with the company online.There are currently fewer job openings (22) compared to previous periods, suggesting possible cost-cutting measures or slowed growth.Recursion Pharmaceuticals' employee business outlook seems neutral with only about half (52%) reporting positive sentiment.Social media following has been growing rapidly especially on Twitter (84 .4%) and Facebook (49 .9%) over the last 90 days, indicating increasing visibility and potentially positive sentiment among the public.
Conclusion
In conclusion, Recursion Pharmaceuticals' financial performance shows some concerning signs with negative gross profit and operating income. However, its stock price has shown recent strength and is trading above its 200-day moving average. The company's alternative data signals present a mixed picture with decreasing job openings and website traffic but strong growth in social media followers. Overall, the analysis of Recursion Pharmaceuticals' stock performance is neutral.
Note: This AI Stock Analysis is based on data as of October 18. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.66, will... Sign up to access price prediction.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.4B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.27 0.8% |
7 |
 |
Inovio Pharmaceuticals INO |
$2.27 2.6% |
2 |
 |
Moderna MRNA |
$26.58 3.3% |
4 |
 |
Anavex Life Sciences AVXL |
$9.25 1.1% |
5 |
 |
BridgeBio Pharma BBIO |
$53.24 2.1% |
6 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 68352 monthly visitors to recursion.com.
-
Web Traffic
68352
-
Change from Previous Month
0.2%
-
3 Month Change
5.3%
-
YoY Change
5.3%
Stocktwits Mentions
Recursion Pharmaceuticals has been mentioned an estimated 784 times on Stocktwits over the last 24 hours.
-
Stocktwits Mentions
784
-
Daily Change
0.3%
-
1 Month Change
333.1%
Twitter Followers
Recursion Pharmaceuticals has 15,716 Twitter Followers on its main Twitter (also known as X) account, which is up by 2.5% over the last month.
-
Twitter Followers
15716
-
Daily Change
0%
-
1 Month Change
2.5%
-
3 Month Change
5.6%
-
YoY Change
5.6%
Facebook Engagement
Recursion Pharmaceuticals has engaged 16 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
16
-
Daily Change
60%
-
1 Month Change
33.3%
-
3 Month Change
77.8%
-
YoY Change
77.8%
Youtube Subscribers
Recursion Pharmaceuticals has 34,700 subscribers on its main Youtube channel, up by 55.6% over the last month.
-
Youtube Subscribers
34700
-
Daily Change
1.2%
-
1 Month Change
55.6%
-
3 Month Change
778.5%
-
YoY Change
778.5%
Job Postings
Recursion Pharmaceuticals has an estimated 23 open job postings, which is down -11.5% over the last month.
-
Job Postings
23
-
Daily Change
4.5%
-
1 Month Change
11.5%
-
3 Month Change
25.8%
-
YoY Change
25.8%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 5 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
5
-
Daily Change
150%
-
1 Month Change
400%
-
3 Month Change
16.7%
Reddit Sentiment
The sentiment Score for Recursion Pharmaceuticals is 39 out of 100, which represents a bearish sentiment.
-
Reddit Sentiment
38.8333
-
Daily Change
48.3%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 52 out of 100 (neutral).
-
Business Outlook
52
-
Change from Previous Month
4%
-
3 Month Change
4%
-
YoY Change
4%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$14.7M
-
Net Income
-$202.5M
-
Earnings per Share
-$0.5
-
Free cash flow
-$133.8M
-
EBITDA
-$191.4M
-
EBITDA Ratio
-12.9785
-
Total Assets
$1.3B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $5.66.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.4B.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $5.85 in 2026. Starting from the current price of $5.66, this represents a 3.4% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.